WO2020210320A8 - L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées - Google Patents

L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées Download PDF

Info

Publication number
WO2020210320A8
WO2020210320A8 PCT/US2020/027218 US2020027218W WO2020210320A8 WO 2020210320 A8 WO2020210320 A8 WO 2020210320A8 US 2020027218 W US2020027218 W US 2020027218W WO 2020210320 A8 WO2020210320 A8 WO 2020210320A8
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolo
pyrimidin
dihydro
ones
substituted
Prior art date
Application number
PCT/US2020/027218
Other languages
English (en)
Other versions
WO2020210320A1 (fr
Inventor
Peter Qinhua HUANG
Kevin Duane BUNKER
Brant Clayton Boren
Aditya Krishnan UNNI
Sunny Abraham
Original Assignee
Recurium Ip Holdings, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings, Llc filed Critical Recurium Ip Holdings, Llc
Publication of WO2020210320A1 publication Critical patent/WO2020210320A1/fr
Publication of WO2020210320A8 publication Critical patent/WO2020210320A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de formule (I). De tels composés, ainsi que des sels pharmaceutiquement acceptables et des compositions de ceux-ci, sont utiles pour traiter des maladies ou des affections, y compris des affections caractérisées par une prolifération cellulaire excessive, telles que le cancer du sein.
PCT/US2020/027218 2019-04-11 2020-04-08 L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées WO2020210320A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832529P 2019-04-11 2019-04-11
US62/832,529 2019-04-11

Publications (2)

Publication Number Publication Date
WO2020210320A1 WO2020210320A1 (fr) 2020-10-15
WO2020210320A8 true WO2020210320A8 (fr) 2020-11-12

Family

ID=72750610

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/027218 WO2020210320A1 (fr) 2019-04-11 2020-04-08 L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées

Country Status (1)

Country Link
WO (1) WO2020210320A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111902413B (zh) 2018-03-09 2023-10-17 里科瑞尔姆Ip控股有限责任公司 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮
JP2024517085A (ja) * 2021-04-12 2024-04-19 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 子宮漿液性がんを治療するためのｗｅｅ１化合物
CN117751122A (zh) * 2021-08-11 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
US8329711B2 (en) * 2007-10-23 2012-12-11 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
WO2019028008A1 (fr) * 2017-08-01 2019-02-07 Zeno Royalties & Milestones, LLC Analogues de 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-one
EP3694861A4 (fr) * 2017-10-09 2021-05-19 Nuvation Bio Inc. Composés hétérocycliques et leurs utilisations
CN111902413B (zh) * 2018-03-09 2023-10-17 里科瑞尔姆Ip控股有限责任公司 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮

Also Published As

Publication number Publication date
WO2020210320A1 (fr) 2020-10-15

Similar Documents

Publication Publication Date Title
WO2019173082A8 (fr) L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
WO2019139899A8 (fr) Composés benzamide
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
WO2020210320A8 (fr) L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
WO2020257549A3 (fr) Composés pour le traitement de maladies pd-l1
CR20210626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
TW200745066A (en) Novel PTP1B inhibitors
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
WO2005105753A8 (fr) Derives naphthalimides, procedes de fabrication et compositions pharmaceutiques les renfermant
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX2021007247A (es) Derivados de rapamicina.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2020008816A (es) Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
MX2021002188A (es) Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.
WO2008087514A3 (fr) Inhibiteurs d'hdac
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MX2023000333A (es) Sales y formas de un inhibidor wee1.
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
MX2022000308A (es) Formulacion de nanoparticulas de inhibidor de bcl-2.
WO2020251871A3 (fr) Nouveaux composés de tétrahydroquinoléine substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20787027

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20787027

Country of ref document: EP

Kind code of ref document: A1